ImmunityBio (IBRX) Free Cash Flow (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Free Cash Flow data on file, last reported at -$77.2 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$77.2 million, up 10.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$300.1 million (up 18.66% YoY), and the FY2025 annual result was -$308.8 million, up 21.08% from the prior year.
• Free Cash Flow fell to -$77.2 million in Q1 2026 per IBRX's latest filing, from -$71.3 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$70.5 million in Q3 2025 and troughed at -$123.2 million in Q4 2023.
• A 5-year average of -$89.7 million and a median of -$85.9 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow slumped 51.25% in 2022, then surged 34.78% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$91.0 million in 2022, then plunged by 35.49% to -$123.2 million in 2023, then surged by 34.78% to -$80.4 million in 2024, then advanced by 11.31% to -$71.3 million in 2025, then retreated by 8.27% to -$77.2 million in 2026.
• Business Quant data shows IBRX's Free Cash Flow at -$77.2 million in Q1 2026, -$71.3 million in Q4 2025, and -$70.5 million in Q3 2025.